keynatinib (TL007) / Medolution, Logix Pharma - LARVOL DELTA

Keynatinib in Treated Patients with NSCLC and Brain Metastases (clinicaltrials.gov) - P2 | N=16 | Completed | Sponsor: Medolution Ltd. | N=30 ➔ 16 | Trial completion date: Jul 2025 ➔ Dec 2024 | Trial primary completion date: Apr 2025 ➔ Dec 2024 | Recruiting ➔ Completed

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: Medolution Ltd. | Trial completion date: Apr 2024 ➔ Apr 2028 | Trial primary completion date: Oct 2023 ➔ Oct 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1

Keynatinib in Treated Patients With NSCLC and Brain Metastases (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Medolution Ltd. | Trial completion date: Jul 2024 ➔ Jul 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Keynatinib in Treated Patients With NSCLC and Brain Metastases (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Medolution Ltd. | Trial completion date: Jul 2022 ➔ Jul 2024 | Trial primary completion date: Apr 2022 ➔ Apr 2024

Trial completion date • Trial primary completion date • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: Medolution Ltd. | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Oct 2022 ➔ Oct 2023

Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1

Keynatinib in Treated Patients With NSCLC and Brain Metastases (clinicaltrials.gov) - P2; N=30; Recruiting; Sponsor: Medolution Ltd.

New P2 trial • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov) - P1; N=75; Recruiting; Sponsor: Medolution Ltd.

Clinical • New P1 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology